Market Research Reports and Industry Reports

Bladder Cancer - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Bladder Cancer - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Pipeline Review, H2 2017, provides an overview of the Bladder Cancer (Oncology) pipeline landscape.

Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 53, 52, 5, 63, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 2, 10 and 3 molecules, respectively.

Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction 8
Bladder Cancer - Overview 9
Bladder Cancer - Therapeutics Development 10
Bladder Cancer - Therapeutics Assessment 36
Bladder Cancer - Companies Involved in Therapeutics Development 55
Bladder Cancer - Drug Profiles 112
Bladder Cancer - Dormant Projects 894
Bladder Cancer - Discontinued Products 901
Bladder Cancer - Product Development Milestones 903
Appendix 914

List Of Tables

List of Tables
Number of Products under Development for Bladder Cancer, H2 2017 32
Number of Products under Development by Companies, H2 2017 34
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 35
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 36
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 37
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 38
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 39
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 40
Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 41
Number of Products under Development by Universities/Institutes, H2 2017 42
Products under Development by Companies, H2 2017 44
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 45
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 46
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 47
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 48
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 49
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 50
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 51
Products under Development by Companies, H2 2017 (Contd..8), H2 2017 52
Products under Development by Companies, H2 2017 (Contd..9), H2 2017 53
Products under Development by Companies, H2 2017 (Contd..10), H2 2017 54
Products under Development by Companies, H2 2017 (Contd..11), H2 2017 55
Products under Development by Universities/Institutes, H2 2017 56
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 57
Number of Products by Stage and Target, H2 2017 59
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 60
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 61
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 62
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 63
Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 64
Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017 65
Number of Products by Stage and Mechanism of Action, H2 2017 67
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 68
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 69
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 70
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 71
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 72
Number of Products by Stage and Route of Administration, H2 2017 74
Number of Products by Stage and Molecule Type, H2 2017 76
Bladder Cancer - Pipeline by 4SC AG, H2 2017 77
Bladder Cancer - Pipeline by Abivax SA, H2 2017 77
Bladder Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2017 78
Bladder Cancer - Pipeline by ADC Therapeutics Sarl, H2 2017 78
Bladder Cancer - Pipeline by Altor BioScience Corp, H2 2017 79
Bladder Cancer - Pipeline by AndroScience Corp, H2 2017 79
Bladder Cancer - Pipeline by ANP Technologies Inc, H2 2017 79
Bladder Cancer - Pipeline by APIM Therapeutics AS, H2 2017 80
Bladder Cancer - Pipeline by Archivel Farma SL, H2 2017 80
Bladder Cancer - Pipeline by Argos Therapeutics Inc, H2 2017 81
Bladder Cancer - Pipeline by Arno Therapeutics Inc, H2 2017 81
Bladder Cancer - Pipeline by Array BioPharma Inc, H2 2017 81
Bladder Cancer - Pipeline by Asana BioSciences LLC, H2 2017 82
Bladder Cancer - Pipeline by Asieris Pharmaceuticals Co Ltd, H2 2017 82
Bladder Cancer - Pipeline by Astellas Pharma Inc, H2 2017 83
Bladder Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2017 83
Bladder Cancer - Pipeline by AstraZeneca Plc, H2 2017 84
Bladder Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017 84
Bladder Cancer - Pipeline by Bavarian Nordic A/S, H2 2017 85
Bladder Cancer - Pipeline by Bayer AG, H2 2017 85
Bladder Cancer - Pipeline by Biocad, H2 2017 86
Bladder Cancer - Pipeline by BioCancell Ltd, H2 2017 86
Bladder Cancer - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2017 87
Bladder Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2017 87
Bladder Cancer - Pipeline by Biotest AG, H2 2017 87
Bladder Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017 88
Bladder Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017 88
Bladder Cancer - Pipeline by Celgene Corp, H2 2017 89
Bladder Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017 90
Bladder Cancer - Pipeline by Celprogen Inc, H2 2017 90
Bladder Cancer - Pipeline by Celsion Corp, H2 2017 90
Bladder Cancer - Pipeline by Celyad SA, H2 2017 91
Bladder Cancer - Pipeline by Cleveland BioLabs Inc, H2 2017 91
Bladder Cancer - Pipeline by Cold Genesys Inc, H2 2017 92
Bladder Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2017 92
Bladder Cancer - Pipeline by CytomX Therapeutics Inc, H2 2017 93
Bladder Cancer - Pipeline by Cytori Therapeutics Inc, H2 2017 93
Bladder Cancer - Pipeline by Daiichi Sankyo Co Ltd, H2 2017 94
Bladder Cancer - Pipeline by Eisai Co Ltd, H2 2017 94
Bladder Cancer - Pipeline by Eleven Biotherapeutics Inc, H2 2017 95
Bladder Cancer - Pipeline by Eli Lilly and Co, H2 2017 95
Bladder Cancer - Pipeline by Elsalys Biotech SAS, H2 2017 96
Bladder Cancer - Pipeline by EpiThany Inc, H2 2017 96
Bladder Cancer - Pipeline by Esperance Pharmaceuticals Inc, H2 2017 96
Bladder Cancer - Pipeline by Exelixis Inc, H2 2017 97
Bladder Cancer - Pipeline by Exicure Inc, H2 2017 97
Bladder Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 98
Bladder Cancer - Pipeline by Five Prime Therapeutics Inc, H2 2017 98
Bladder Cancer - Pipeline by Gene Signal International SA, H2 2017 99
Bladder Cancer - Pipeline by Genentech Inc, H2 2017 99
Bladder Cancer - Pipeline by Genmab A/S, H2 2017 99
Bladder Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017 100
Bladder Cancer - Pipeline by H3 Biomedicine Inc, H2 2017 100
Bladder Cancer - Pipeline by Hamlet Pharma AB, H2 2017 101
Bladder Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 101
Bladder Cancer - Pipeline by HitGen LTD, H2 2017 102
Bladder Cancer - Pipeline by Horizon Pharma Plc, H2 2017 102
Bladder Cancer - Pipeline by Immunocore Ltd, H2 2017 102
Bladder Cancer - Pipeline by Immunomedics Inc, H2 2017 103
Bladder Cancer - Pipeline by Immupharma Plc, H2 2017 103
Bladder Cancer - Pipeline by Imugene Ltd, H2 2017 104
Bladder Cancer - Pipeline by Incanthera Ltd, H2 2017 104
Bladder Cancer - Pipeline by Incyte Corp, H2 2017 105
Bladder Cancer - Pipeline by Innovation Pharmaceuticals Inc, H2 2017 105
Bladder Cancer - Pipeline by InteRNA Technologies BV, H2 2017 106
Bladder Cancer - Pipeline by Iovance Biotherapeutics Inc, H2 2017 106
Bladder Cancer - Pipeline by Johnson & Johnson, H2 2017 107
Bladder Cancer - Pipeline by Kite Pharma Inc, H2 2017 107
Bladder Cancer - Pipeline by Laboratoires Pierre Fabre SA, H2 2017 108
Bladder Cancer - Pipeline by LipoMedix Pharmaceutical Inc, H2 2017 108
Bladder Cancer - Pipeline by Loxo Oncology Inc, H2 2017 108
Bladder Cancer - Pipeline by Lycera Corp, H2 2017 109
Bladder Cancer - Pipeline by MacroGenics Inc, H2 2017 109
Bladder Cancer - Pipeline by Marina Biotech Inc, H2 2017 110
Bladder Cancer - Pipeline by MaxiVAX SA, H2 2017 110
Bladder Cancer - Pipeline by Medicenna Therapeutics Corp, H2 2017 110
Bladder Cancer - Pipeline by MedImmune LLC, H2 2017 111
Bladder Cancer - Pipeline by Merck & Co Inc, H2 2017 112
Bladder Cancer - Pipeline by Merck KGaA, H2 2017 112
Bladder Cancer - Pipeline by Mirati Therapeutics Inc, H2 2017 113
Bladder Cancer - Pipeline by Moleculin Biotech Inc, H2 2017 113
Bladder Cancer - Pipeline by MTG Biotherapeutics Inc, H2 2017 113
Bladder Cancer - Pipeline by NanoCarrier Co Ltd, H2 2017 114
Bladder Cancer - Pipeline by NantKwest Inc, H2 2017 114
Bladder Cancer - Pipeline by Nektar Therapeutics, H2 2017 115
Bladder Cancer - Pipeline by Novartis AG, H2 2017 115
Bladder Cancer - Pipeline by OncoTherapy Science Inc, H2 2017 116
Bladder Cancer - Pipeline by Oncovir Inc, H2 2017 116
Bladder Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 117
Bladder Cancer - Pipeline by Optimum Therapeutics LLC, H2 2017 117
Bladder Cancer - Pipeline by Oxford BioTherapeutics Ltd, H2 2017 117
Bladder Cancer - Pipeline by Pfizer Inc, H2 2017 118
Bladder Cancer - Pipeline by Pharma Mar SA, H2 2017 118
Bladder Cancer - Pipeline by Philogen SpA, H2 2017 119
Bladder Cancer - Pipeline by Pieris Pharmaceuticals Inc, H2 2017 119
Bladder Cancer - Pipeline by Plexxikon Inc, H2 2017 120
Bladder Cancer - Pipeline by Polaris Pharmaceuticals Inc, H2 2017 120
Bladder Cancer - Pipeline by Provecs Medical GmbH (Inactive), H2 2017 120
Bladder Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H2 2017 121
Bladder Cancer - Pipeline by PsiOxus Therapeutics Ltd, H2 2017 121
Bladder Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2017 122
Bladder Cancer - Pipeline by Samyang Holdings Corp, H2 2017 122
Bladder Cancer - Pipeline by Sanofi, H2 2017 123
Bladder Cancer - Pipeline by Sareum Holdings Plc, H2 2017 123
Bladder Cancer - Pipeline by Shionogi & Co Ltd, H2 2017 124
Bladder Cancer - Pipeline by Sierra Oncology Inc, H2 2017 124
Bladder Cancer - Pipeline by Sillajen Biotherapeutics, H2 2017 124
Bladder Cancer - Pipeline by Sitka Biopharma Inc, H2 2017 125
Bladder Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2017 125
Bladder Cancer - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017 126
Bladder Cancer - Pipeline by Stemline Therapeutics Inc, H2 2017 126
Bladder Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 127
Bladder Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2017 127
Bladder Cancer - Pipeline by Taris Biomedical LLC, H2 2017 128
Bladder Cancer - Pipeline by Theralase Technologies Inc, H2 2017 128
Bladder Cancer - Pipeline by Tocagen Inc, H2 2017 129
Bladder Cancer - Pipeline by Tolero Pharmaceuticals Inc, H2 2017 129
Bladder Cancer - Pipeline by Transgene SA, H2 2017 129
Bladder Cancer - Pipeline by UroGen Pharma Ltd, H2 2017 130
Bladder Cancer - Pipeline by Vaccibody AS, H2 2017 130
Bladder Cancer - Pipeline by Vakzine Projekt Management GmbH, H2 2017 131
Bladder Cancer - Pipeline by Vault Pharma Inc, H2 2017 131
Bladder Cancer - Pipeline by Vaxeal Holding SA, H2 2017 131
Bladder Cancer - Pipeline by Vaxiion Therapeutics Inc, H2 2017 132
Bladder Cancer - Pipeline by Viralytics Ltd, H2 2017 132
Bladder Cancer - Pipeline by Vyriad Inc, H2 2017 133
Bladder Cancer - Pipeline by Zymeworks Inc, H2 2017 133
Bladder Cancer - Dormant Projects, H2 2017 916
Bladder Cancer - Dormant Projects, H2 2017 (Contd..1), H2 2017 917
Bladder Cancer - Dormant Projects, H2 2017 (Contd..2), H2 2017 918
Bladder Cancer - Dormant Projects, H2 2017 (Contd..3), H2 2017 919
Bladder Cancer - Dormant Projects, H2 2017 (Contd..4), H2 2017 920
Bladder Cancer - Dormant Projects, H2 2017 (Contd..5), H2 2017 921
Bladder Cancer - Dormant Projects, H2 2017 (Contd..6), H2 2017 922
Bladder Cancer - Discontinued Products, H2 2017 923
Bladder Cancer - Discontinued Products, H2 2017 (Contd..1), H2 2017 924

EMEA (Europe, Middle East and Africa) Portable Bladder Scanners Market Report 2017

In this report, the EMEA Portable Bladder Scanners market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022,

USD 4000View Report

Bladder Cancer - Pipeline Review, H2 2017

Bladder Cancer - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Pipeline Review, H2 2017, provides an overview of the Bladder Cancer

USD 2000View Report

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in

USD 3995View Report

Small-Cell Lung Cancer - Pipeline Review, H2 2017

Small-Cell Lung Cancer - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer - Pipeline Review, H2 2017, provides an overview of the

USD 2000View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


+91 9987 2952 42

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Nov 2017
No. of Pages :937
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube